The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study.

ABSTRACT:

Objective

Given a man's current prostate- specific antigen (PSA) level, age and family history of prostate cancer, what are the benefits (decreased risk of higher Gleason score [GS] cancer at diagnosis) and harms (increased risk of false-positive biopsy recommendation) of waiting 1, 2, 3, 4 or 5-8 years until the next PSA test?

Design

Prospective cohort.

Setting

All PSA tested men in Stockholm, Sweden, between 2003 and 2015.

Participants

Men aged 50-74 years with at least two PSA tests between 2003 and 2015 (n=174 636).

Main outcome measures

Log-binomial regression to calculate the risk ratio (RR) of GS ≥7 and GS 6 versus benign outcome at prostate biopsy and 12-year cumulative probability of experiencing a false-positive biopsy by testing interval, age,

SUBMITTER: Palsdottir T 

PROVIDER: S-EPMC6475177 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature